Trending...
- Garment Saver Launches Eco-Friendly, Made-To-Order Wedding Party Gifts - 129
- Las Vegas Comedian Don Barnhart Brings Valentine's Day Laughter to Merced - 118
- Epic Pictures' DREAD Label Hits the Market with Horror-Comedy For Sale By Exorcist
ANNAPOLIS, Md., Jan. 10, 2025 ~ In an exciting announcement, Alphyn, a clinical-stage dermatology company, revealed that their CEO Neal Koller will be presenting at several investor conferences during the upcoming J.P. Morgan Healthcare Week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
- Graphic EZ Print Launches New Website, Revolutionizing Gardena's Printing Experience!
- California: Governor Newsom issues emergency proclamation to help Santa Cruz recover from destructive winter storms
- 19th Century Serial Killer as Modern Feminist Antihero
- California: Governor Newsom marks new milestone in Delta Conveyance Project
- Rutgers University Student Wins "New Jersey's Top Student Entrepreneur" in EO's Global Student Entrepreneur Awards
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
Filed Under: Business
0 Comments
Latest on The Californer
- GRAVITY 180 Releases "Overjoyed", A Romantic Homage to Stevie Wonder's Original on Valentine's Day
- Tax Deductions People Don't Know About
- PODS Local Has Storage Solutions for Spring Cleaning
- Authority Property Management Wins 2024 Record Searchlight "Best of the North State" Award
- KessCo Partners with Bandai to Launch "Tamagotchi Collections" Board Game
- Omnific Publishing Announces the Release of Past Perfect Vacation by Deborah Chantson
- 100FilmsRetreat.com Opened Today for Short Film and Video Submissions to Screen & Compete in SoCal
- California: Governor Newsom cuts more red tape by further streamlining permitting laws to accelerate rebuilding Los Angeles
- The Jaime & Blanca Jarrín Foundation Golf Classic Raises Vital Funds for Southern California Wildfire Relief Efforts
- Cloud Dominates AI Deployment as Developers Leverage Scalable Environments
- Global Digital Currency & Wealth Management Leader; Breakout 388% FY2025 Revenue Growth Over $19.7 Million: Metalpha Technology (Stock Symbol: MATH)
- Airbnb Announces Fourth Quarter and Full Year 2024 Results
- InterMountain Opens Urban Inspired Aloft Sacramento Airport Natomas
- OEM Technology Partnerships Launches Brokerage Specializing in 100+ OEM Technologies
- Restoring Excellence With Porsche and Bennett Awards
- Kelly Sue Milano, co-creator of Hex11, joins Immortal Studios as VP of content and executive editor of the Immortal Storyverse
- Integral Ad Science Holding Corp. (IAS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Dr. Eunice Moseley Accepts Adjunct Faculty Position at Stanton University
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity
- Notable Announces New Partner Program - Expanding the Network of Experts Who Can Drive AI Adoption in Healthcare